Octopus Overlords

dbt1949 wrote: Mon Jan 25, 2021 3:53 pm I need a better reason.

dbt1949 wrote: Mon Jan 25, 2021 3:53 pm I need a better reason.

dbt1949 wrote: Mon Jan 25, 2021 3:53 pm I need a better reason.

Do you like when people in your extended family have the ability to freely come and go

the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.

A new study from Israel's Sheba Medical Center in Tel Hashomer suggested that the Pfizer vaccine does, in fact, reduce transmission. The small study of 102 medical workers found that after the second dose of the vaccine, 100 of the subjects had significantly higher levels of antibodies than even people who recovered from severe COVID-19 infections, The Jerusalem Post reports.

"The results of the survey are in line with Pfizer's experiment and even better than expected," said Prof. Gili Regev-Yochay, director of Sheba's Infectious Disease Epidemiology Unit. "I expect that the survey results of the other employees participating will be similar. There is certainly reason for optimism." It isn't clear how long immunity will last, and the results are preliminary, but Regev-Yochay said it appears to her that fully vaccinate people won't shed the virus, meaning they won't pass it on to others.

"People who have received both doses of the vaccine have levels of antibodies ranging from six to 59," Regev-Yochay said. "These are high values, and it's encouraging and reasonable to assume that these people will not be carriers or contagious, although that is still not a direct conclusion." Israel is the first country to have vaccinated nearly a quarter of its population, making it a valuable resource for vaccine developers and public health experts.

Defiant wrote: Tue Jan 26, 2021 3:31 pm According to a friend in the J&J trial, he's heard that:

The preliminary results from the trial will be released in a few days, and they plan to unblind those in the trial in about a month.

disarm wrote: Tue Jan 26, 2021 8:47 pm I got my second dose of the Moderna vaccine at noon yesterday and it's been an interesting 24 hours. I started getting some pretty significant arm soreness after a couple hours, but nothing too different than the first round. By the time I was heading to bed around 10:00, it was a much different story. I spiked a fever close to 102 and developed the most intense rigors (shaking chills) that I've ever experienced... took some tylenol, curled up under an electric blanket turned up all the way, a down comforter on top of that, and still couldn't stop shaking for almost 90 minutes. It eventually stopped and I tried to get some sleep, but my whole body ached to the point that I couldn't get comfortable to fall asleep...wound up fading in and out for the rest of the night. My fever finally broke around 7am, after a second round of tylenol, and I've been getting progressively better throughout the day. I've felt close to normal since I hit 24-hour post-injection, but the twelve hours from 10pm-10am were pretty rough.

Do I regret getting the vaccine? Not in the slightest, and I will continue to recommend that everyone else get in line as soon as you have the opportunity. I fell in the "lucky" 50% that's have a strong response to the second dose, but it really didn't last long and is a small price to pay for the confidence that I shouldn't have to worry about catching a significant case of COVID now. I will, however, recommend that everyone consider planning a day off from work after the second dose. Luckily, I'm off from work this week anyway and it didn't interfere with life too much.

So that's two adults in my house vaccinated now...two doses of Moderna for me, and two of the Pfizer vaccine for my wife. She was the lucky one...barely felt different at all with her second shot.

Smoove_B wrote: Sat Jan 23, 2021 6:35 pm

Hrdina wrote: Fri Jan 22, 2021 11:41 pm I just got an email from the State of New Jersey which can be paraphrased as "You are eligible to get a COVID-19 vaccine; good luck finding any".

As someone with insider information, I'm just recently learning how much of a cluster F this entire thing is and the amount of skullduggery that's happening as line-jumpers coordinate the targeting of vaccination slots. Our state should be stepping in and acting as true gate keepers in this process, but instead it has turned into the vaccination equivalent of dealing with ticket scalpers. It's beyond shameful and I continue to be embarrassed for my profession.

YellowKing wrote: Wed Jan 27, 2021 8:49 am Just anecdotally hearing stories from my co-workers, the ratio of people who had a bad reaction to the second shot vs nothing is about 9:1. Our organization actually scheduled all employee vaccinations on Fri/Sat because so many people were having to take leave after the second shot. I'm planning on taking half a day off and pounding Tylenol.

malchior wrote: Wed Jan 27, 2021 10:15 am

Smoove_B wrote: Sat Jan 23, 2021 6:35 pm

Hrdina wrote: Fri Jan 22, 2021 11:41 pm I just got an email from the State of New Jersey which can be paraphrased as "You are eligible to get a COVID-19 vaccine; good luck finding any".

As someone with insider information, I'm just recently learning how much of a cluster F this entire thing is and the amount of skullduggery that's happening as line-jumpers coordinate the targeting of vaccination slots. Our state should be stepping in and acting as true gate keepers in this process, but instead it has turned into the vaccination equivalent of dealing with ticket scalpers. It's beyond shameful and I continue to be embarrassed for my profession.

So today was a fun day. My wife works in a factory and is in an essential worker group here in NJ - aka 1B. We've been unable to get her an appointment even though both of us are eligible (I'm in 1C which they released as well). She has to go in still so we have working to her the appointment and we'll see for me. She has now seen several of her co-workers get it and its all through weird back channels. One just called her and gave her the secret handshake about how *he* got the vaccine. The best part? He wasn't even in the eligible pool. Cool story. Now we have to see if she can wheedle an appointment through this contact. Are you kidding me? The way this is happening is beyond aggravating. We both registered with the state and get zero information but if you know somebody who knows somebody then you get it.

After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer [GMT], 224 to 354), regardless of vaccine dose or age group, and reached 100% by day 57 with a further increase in titers (GMT, 288 to 488) in cohort 1a. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.

hitbyambulance wrote: Thu Jan 28, 2021 1:50 am J&J Ad26.COV2.S interim results

After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer [GMT], 224 to 354), regardless of vaccine dose or age group, and reached 100% by day 57 with a further increase in titers (GMT, 288 to 488) in cohort 1a. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.

Phase III results should be out by Friday

dbt1949 wrote: Mon Jan 25, 2021 3:53 pmI need a better reason.

stessier wrote: Thu Jan 28, 2021 12:17 pm

hitbyambulance wrote: Thu Jan 28, 2021 1:50 am J&J Ad26.COV2.S interim results

After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer [GMT], 224 to 354), regardless of vaccine dose or age group, and reached 100% by day 57 with a further increase in titers (GMT, 288 to 488) in cohort 1a. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.

Phase III results should be out by Friday

Do you have a link for that?

Isgrimnur wrote: Thu Jan 28, 2021 12:24 pm https://www.nejm.org/doi/10.1056/NEJMoa2034201

hitbyambulance wrote: Thu Jan 28, 2021 3:57 pm

stessier wrote: Thu Jan 28, 2021 12:17 pm

hitbyambulance wrote: Thu Jan 28, 2021 1:50 am J&J Ad26.COV2.S interim results

After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer [GMT], 224 to 354), regardless of vaccine dose or age group, and reached 100% by day 57 with a further increase in titers (GMT, 288 to 488) in cohort 1a. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.

Phase III results should be out by Friday

Do you have a link for that?

Isgrimnur wrote: Thu Jan 28, 2021 12:24 pm https://www.nejm.org/doi/10.1056/NEJMoa2034201

The biotech company Novavax says its COVID-19 vaccine is 89% effective at preventing the illness, according to an interim analysis of a large study conducted in the U.K.

The results come from a clinical trial involving more than 15,000 volunteers, of whom more than a quarter were older than 65.

The company says 62 cases of COVID-19 were seen in the study. Fifty-six occurred in the group that got placebo; six were seen in people who received the vaccine.
Health

The Novavax vaccine is what's called a protein subunit vaccine, a different kind of vaccine technology that is used in the shots made by Pfizer and Moderna that are being rolled out in this country. The Novavax vaccine is given in two doses spaced 21 days apart.

Novavax says in a news release that its vaccine is slightly less effective against the new variant of the coronavirus that's been circulating in the U.K. — about 86%. Against the original COVID-19 strain, the vaccine is about 96% effective, the company says.

In a separate, smaller study in South Africa, the vaccine was still somewhat effective at preventing COVID disease — 49% overall — a level far lower than in the larger U.K. study. But there is a wide range of uncertainty around exactly how much lower the effectiveness is.

dbt1949 wrote: Thu Jan 28, 2021 11:03 pm Is 89% effective good enough? 1 in 10 having problems?

A single-shot coronavirus vaccine from pharmaceutical giant Johnson & Johnson was 66 percent effective at preventing moderate and severe illness in a massive global trial, findings released Friday show. But its performance was stronger in the United States and weaker in South Africa, where a worrisome coronavirus variant now dominates — a complicated result that reflects the evolution of the pandemic.

The vaccine was 72 percent effective at protecting against moderate to severe illness in the United States, but it was 66 percent effective in Latin America and 57 percent effective in South Africa, where concerning variants have taken root. It was 85 percent effective overall at preventing severe disease.

disarm wrote: Tue Jan 26, 2021 8:47 pm I got my second dose of the Moderna vaccine at noon yesterday and it's been an interesting 24 hours. I started getting some pretty significant arm soreness after a couple hours, but nothing too different than the first round. By the time I was heading to bed around 10:00, it was a much different story. I spiked a fever close to 102 and developed the most intense rigors (shaking chills) that I've ever experienced... took some tylenol, curled up under an electric blanket turned up all the way, a down comforter on top of that, and still couldn't stop shaking for almost 90 minutes. It eventually stopped and I tried to get some sleep, but my whole body ached to the point that I couldn't get comfortable to fall asleep...wound up fading in and out for the rest of the night. My fever finally broke around 7am, after a second round of tylenol, and I've been getting progressively better throughout the day. I've felt close to normal since I hit 24-hour post-injection, but the twelve hours from 10pm-10am were pretty rough.

dbt1949 wrote: Thu Jan 28, 2021 11:03 pm Is 89% effective good enough? 1 in 10 having problems?

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Max Peck wrote: Fri Jan 29, 2021 12:14 pm Another significant factor is that the J&J vaccine seems to result in milder symptoms even when it doesn't prevent COVID-19 outright.

One-dose shot offers good protection, new hope against virus

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Even if the J&J vaccine isn't as effective in preventing COVID-19 as the 2-dose mRNA vaccines, it seems like it is extremely effective at preventing hospitalization and death from the disease, including the more infectious and possibly more virulent strains.

sn't that similar to the flu vaccine?

CDC Morbidity and Mortality Weekly Report, the current influenza vaccine has been 45% effective overall against 2019-2020 seasonal influenza A and B viruses. Specifically, the flu vaccine has been 50% effective against influenza B/Victoria viruses and 37% effective against influenza A(H1N1)pdm09

Lorini wrote: Fri Jan 29, 2021 12:39 pm

Max Peck wrote: Fri Jan 29, 2021 12:14 pm Another significant factor is that the J&J vaccine seems to result in milder symptoms even when it doesn't prevent COVID-19 outright.

One-dose shot offers good protection, new hope against virus

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Even if the J&J vaccine isn't as effective in preventing COVID-19 as the 2-dose mRNA vaccines, it seems like it is extremely effective at preventing hospitalization and death from the disease, including the more infectious and possibly more virulent strains.

Isn't that similar to the flu vaccine?